Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(100.0%)
2Total
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07331818Phase 2Not Yet Recruiting

Luspatercept in Patients Affected With Rare Inherited Anemias

Role: lead

NCT06213402Recruiting

RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)

Role: collaborator

NCT05935202Phase 2Not Yet Recruiting

Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies

Role: lead

All 3 trials loaded